


Ordering Information

Guidewire compatibility: 0.018"/ 0.035"



0.018"		Balloon Diameter			
Balloon Length		4.00 mm	5.00 mm	6.00 mm	8.00 mm
20 mm		ASD18-4020A/B/C	ASD18-5020A/B/C	ASD18-6020A/B/C	ASD18-8020A/B/C
40 mm		ASD18-4040A/B/C	ASD18-5040A/B/C	ASD18-6040A/B/C	ASD18-8040A/B/C
60 mm		ASD18-4060A/B/C	ASD18-5060A/B/C	ASD18-6060A/B/C	ASD18-8060A/B/C
80 mm		ASD18-4080A/B/C	ASD18-5080A/B/C	ASD18-6080A/B/C	ASD18-8080A/B/C
Nominal Pressure	8 atm				
Rated Burst Pressure	20 atm				18 atm

0.035"		Balloon Diameter			
Balloon Length		4.00 mm	5.00 mm	6.00 mm	8.00 mm
20 mm		ASD35-4020A/B/C	ASD35-5020A/B/C	ASD35-6020A/B/C	ASD35-8020A/B/C
40 mm		ASD35-4040A/B/C	ASD35-5040A/B/C	ASD35-6040A/B/C	ASD35-8040A/B/C
60 mm		ASD35-4060A/B/C	ASD35-5060A/B/C	ASD35-6060A/B/C	ASD35-8060A/B/C
80 mm		ASD35-4080A/B/C	ASD35-5080A/B/C	ASD35-6080A/B/C	ASD35-8080A/B/C
Nominal Pressure	8 atm				
Rated Burst Pressure	20 atm				18 atm

Dissolve™ AV



NC Peripheral Scoring DCB



DK Medical Technology Co.,Ltd.


+86-512-69880808
cs@dkmedtech.com
www.en.dkmedtech.com
Unit #5 Xinhong Park, No. 9 West Suhong Road, Suzhou





High Pressure · Scoring · Drug-coating

3
IN 1

The Third Generation Drug-Coated Balloon





- NMPA Approval 20233030980
- Applicable to percutaneous transluminal angioplasty for stenotic lesions of autologous or artificial arteriovenous dialysis access.




High Pressure

- Highest RBP: 20atm
 - High vessel dilation success rate & Lumen gain
- Premarket RCT clinical trial (NCT04226599)
- Technical success rate:
- Test group **96.33%** vs Control group **91.82%**
- Acute lumen gain:
- Test group **3.40 mm** vs Control group **2.93 mm**



Integrated Scoring Elements

- Highly focused force transmission of scoring element is **598 times** that of the conventional balloon
- Directional, uniform expansion of stenosis
- Good conformability to curved vessel



Drug Coating

- Extended target lesion primary patency
 - Premarket RCT clinical trial (NCT04226599) vs. HP Balloon
- Target lesion primary patency (TLPP) at 6 months:
- N=220 All lesions: Test group **82.7%** vs Control group **58.9%**
- N=40 AVG lesions: Test group **78.3%** vs Control group **29.4%**

